479 related articles for article (PubMed ID: 32860032)
1. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
Budoff MJ; Bhatt DL; Kinninger A; Lakshmanan S; Muhlestein JB; Le VT; May HT; Shaikh K; Shekar C; Roy SK; Tayek J; Nelson JR
Eur Heart J; 2020 Oct; 41(40):3925-3932. PubMed ID: 32860032
[TBL] [Abstract][Full Text] [Related]
2. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
Budoff MJ; Muhlestein JB; Bhatt DL; Le Pa VT; May HT; Shaikh K; Shekar C; Kinninger A; Lakshmanan S; Roy SK; Tayek J; Nelson JR
Cardiovasc Res; 2021 Mar; 117(4):1070-1077. PubMed ID: 32609331
[TBL] [Abstract][Full Text] [Related]
3. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ; Zamorano JL; Parhofer KG
Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
[TBL] [Abstract][Full Text] [Related]
4. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
Budoff M; Brent Muhlestein J; Le VT; May HT; Roy S; Nelson JR
Clin Cardiol; 2018 Jan; 41(1):13-19. PubMed ID: 29365351
[TBL] [Abstract][Full Text] [Related]
5. Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT.
Rabbat MG; Lakshmanan S; Benjamin MM; Doros G; Kinninger A; Budoff MJ; Bhatt DL
Eur Heart J Cardiovasc Imaging; 2023 Jun; 24(7):866-873. PubMed ID: 37082990
[TBL] [Abstract][Full Text] [Related]
6. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
[TBL] [Abstract][Full Text] [Related]
7. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
Brinton EA; Ballantyne CM; Bays HE; Kastelein JJ; Braeckman RA; Soni PN
Cardiovasc Diabetol; 2013 Jul; 12():100. PubMed ID: 23835245
[TBL] [Abstract][Full Text] [Related]
8. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Bazarbashi N; Miller M
Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
[TBL] [Abstract][Full Text] [Related]
9. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
[TBL] [Abstract][Full Text] [Related]
10. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607
[TBL] [Abstract][Full Text] [Related]
11. Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
Alfaddagh A; Elajami TK; Ashfaque H; Saleh M; Bistrian BR; Welty FK
J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29246960
[TBL] [Abstract][Full Text] [Related]
12. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Trivedi K; Le V; Nelson JR
Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
[TBL] [Abstract][Full Text] [Related]
14. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
[TBL] [Abstract][Full Text] [Related]
15. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
Orringer CE; Jacobson TA; Maki KC
J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment.
Weintraub WS; Bhatt DL; Zhang Z; Dolman S; Boden WE; Bress AP; King JB; Bellows BK; Tajeu GS; Derington CG; Johnson J; Andrade K; Steg PG; Miller M; Brinton EA; Jacobson TA; Tardif JC; Ballantyne CM; Kolm P
JAMA Netw Open; 2022 Feb; 5(2):e2148172. PubMed ID: 35157055
[TBL] [Abstract][Full Text] [Related]
17. Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.
Bays HE; Ballantyne CM; Braeckman RA; Stirtan WG; Doyle RT; Philip S; Soni PN; Juliano RA
Metab Syndr Relat Disord; 2015 Aug; 13(6):239-47. PubMed ID: 25893544
[TBL] [Abstract][Full Text] [Related]
18. Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China.
Wang Z; Zhang X; Qu Y; Zhang S; Chen Y; Chen X; Qi X; Liu P; Liu S; Jiang S; Man R; He L; Wu L; Li Z; Shang Y; Qiu Z; Liu F; Xu C; Lai C; Ge J
Lipids Health Dis; 2023 Jun; 22(1):71. PubMed ID: 37301827
[TBL] [Abstract][Full Text] [Related]
19. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
Miller M; Ballantyne CM; Bays HE; Granowitz C; Doyle RT; Juliano RA; Philip S
Am J Cardiol; 2019 Sep; 124(5):696-701. PubMed ID: 31277790
[TBL] [Abstract][Full Text] [Related]
20. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
Gaba P; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Giugliano RP; Martens FMAC; Gibson CM; Ballantyne CM;
J Am Coll Cardiol; 2022 May; 79(17):1660-1671. PubMed ID: 35483753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
